The oral nucleoside prodrug GS-5245 is efficacious against SARS-CoV-2 and other endemic, epidemic, and enzootic coronaviruses.
Saved in:
| Title: | The oral nucleoside prodrug GS-5245 is efficacious against SARS-CoV-2 and other endemic, epidemic, and enzootic coronaviruses. |
|---|---|
| Authors: | Martinez DR; Department of Immunobiology, Yale School of Medicine, New Haven, CT 06510, USA.; Yale Center for Infection and Immunity, Yale School of Medicine, New Haven, CT 06510, USA., Moreira FR; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA., Catanzaro NJ; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA., Diefenbacher MV; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA., Zweigart MR; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA., Gully KL; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA., De la Cruz G; Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA., Brown AJ; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA., Adams LE; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA., Yount B; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA., Baric TJ; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA., Mallory ML; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA., Conrad H; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA., May SR; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA., Dong S; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA., Scobey DT; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA., Nguyen C; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA., Montgomery SA; Department of Pathology and Laboratory Medicine, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA., Perry JK; Gilead Sciences, Inc., Foster City, CA 94404, USA., Babusis D; Gilead Sciences, Inc., Foster City, CA 94404, USA., Barrett KT; Gilead Sciences, Inc., Foster City, CA 94404, USA., Nguyen AH; Gilead Sciences, Inc., Foster City, CA 94404, USA., Nguyen AQ; Gilead Sciences, Inc., Foster City, CA 94404, USA., Kalla R; Gilead Sciences, Inc., Foster City, CA 94404, USA., Bannister R; Gilead Sciences, Inc., Foster City, CA 94404, USA., Feng JY; Gilead Sciences, Inc., Foster City, CA 94404, USA., Cihlar T; Gilead Sciences, Inc., Foster City, CA 94404, USA., Baric RS; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.; Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA.; Rapidly Emerging Antiviral Drug Development Initiative, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA., Mackman RL; Gilead Sciences, Inc., Foster City, CA 94404, USA., Bilello JP; Gilead Sciences, Inc., Foster City, CA 94404, USA., Schäfer A; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.; Rapidly Emerging Antiviral Drug Development Initiative, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA., Sheahan TP; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.; Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA.; Rapidly Emerging Antiviral Drug Development Initiative, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. |
| Source: | Science translational medicine [Sci Transl Med] 2024 May 22; Vol. 16 (748), pp. eadj4504. Date of Electronic Publication: 2024 May 22. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: American Association for the Advancement of Science Country of Publication: United States NLM ID: 101505086 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1946-6242 (Electronic) Linking ISSN: 19466234 NLM ISO Abbreviation: Sci Transl Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
